Robert G. Lerner, M.D.

In the past three years, Dr. Lerner has served as a consultant for RPR, and has served on the Speakers' Bureau for Pharmacia & Upjohn.

This activity is made possible by an unrestricted educational grant from the Novartis Foundation for Gerontology.

Release Date: 09/28/2002
Termination Date: 09/28/2005

Estimated time to complete: 1 hour(s).

Albert Einstein College of Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Upon completion of this Cyberounds^®, the participant should be able to:

• Describe the term "thrombophilia" and list the recently discovered thrombophilic mutations such as Factor V Leiden, Prothrombin G20210A and MTHFR
• Discuss the increased risk of thrombosis for pregnant women with thrombophilia, and the risk of pregnancy loss and complications
• Discuss the preliminary data supportive of enoxaparin to prevent pregnancy loss.

 

This conference may include discussion of commercial products and services.

The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

 

Please click below to accept the terms of this CME activity